DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis

Information source: Olive View-UCLA Education & Research Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pyelonephritis

Intervention: No intervention (Other)

Phase: N/A

Status: Completed

Sponsored by: Olive View-UCLA Education & Research Institute

Summary

Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and vomiting. In the U. S., it is estimated that there are 20 cases of pyelonephritis per 10,000 annually, with the highest incidence in young women. Escherichia coli (E. coli) causes over 80% of these infections. Over the last two decades, E. coli resistance has emerged to commonly prescribed antimicrobials, such as ampicillin and trimethoprim-sulfamethoxazole (TMP/SMX). Most recently, resistance to fluoroquinolones and strains producing extended-spectrum beta-lactamases (ESBL) have been observed. In order to better understand the evolution and current state of antibiotic resistance among E. coli urinary tract isolates so as to better inform treatment decisions, the investigators propose to conduct an investigation to: a) determine the prevalence of antimicrobial resistance among E. coli causing acute pyelonephritis in various patient groups, and specifically healthy community-dwellers with uncomplicated infections, b) determine the specific prevalence of fluoroquinolone-resistance and ESBL-producing E. coli, and c) determine potential risk factors for fluoroquinolone and ESBL-producing E. coli infections.

Clinical Details

Official title: Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Prevalence of antimicrobial resistant E. coli in the U.S.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- patients > 18 years of age with flank pain and/or costovertebral angle tenderness

- documented temperature in the emergency department of ≥38°C/100. 4°F by any method of

measurement,

- documented temperature in the emergency department of ≥38°C/100. 4°F by any method of

measurement, Exclusion Criteria:

- complicated pyelonephritis

Locations and Contacts

Olive View-UCLA Medical Center, Sylmar, California 91342, United States
Additional Information

Starting date: July 2013
Last updated: April 23, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017